Abstract

Objective: We investigated the prevalence, evolution, associated factors, and risk factors of apathy in a cohort of patients with early-stage Parkinson's disease (PD), who underwent a 4-years prospective follow-up.Methods: This study included 188 patients with PD (baseline disease duration <3 years) who underwent an annual evaluation using the Lille Apathy Rating Scale (LARS). Based on the cut-off value of −21 observed on the LARS, patients were categorized as PD with and without apathy. The generalized estimating equations (GEE) model was utilized to determine the factors associated with apathy, and the Cox proportional-hazards regression model was used to determine the predictors of apathy.Results: Apathy increased from a baseline rate of 18.6–28.8% after 4 years; notably, this rate was not persistent across patients' visits. The LARS score was independently associated with the male sex (B 8.131, p = 0.009), low Frontal Assessment Battery (FAB) scores (B 0.567, p = 0.011), low attention scores on the Montreal Cognitive Assessment (MOCA) test (B 0.217, p = 0.026), high Hamilton Depression Rating Scale (HDRS) scores (B 1.362, p < 0.001), high Unified Parkinson's Disease Rating Scale (UPDRS) part III scores (B 1.147, p < 0.001), and prolonged follow-up time (B 1.785, p = 0.048). A high HDRS score was the only predictor of apathy in PD [hazard ratio (HR) 1.043, p = 0.026].Conclusions: The risk of apathy is higher in men with progressive PD accompanied by disease-specific motor and non-motor symptoms. Depression during early-stage PD is a primary risk factor for apathy in PD.

Highlights

  • Apathy, a common neuropsychiatric symptom in patients with Parkinson’s disease (PD), can occur both in the early and advanced stages of PD and may even precede the motor symptoms of the disease (Pagonabarraga et al, 2015)

  • We prospectively investigated patients with early-stage PD, who underwent a 4-years follow-up to determine the prevalence, evolution, associated factors, and risk factors of apathy in patients with PD

  • Baseline antiparkinsonian therapy was administered to 90 patients (47.9%), and this figure increased to 100% after 4 years, with a mean increase in the levodopa equivalent daily doses (LEDD) from 152.5 mg/day (SD 188.1) to 529.8 mg/day (SD 210.7)

Read more

Summary

Introduction

A common neuropsychiatric symptom in patients with Parkinson’s disease (PD), can occur both in the early and advanced stages of PD and may even precede the motor symptoms of the disease (Pagonabarraga et al, 2015). Limited data are available regarding the long-term evolution and trajectory of apathy in patients with early-stage PD; further research is warranted to gain a deeper understanding of the associated and predicted factors of apathy in patients with PD. This information would benefit clinicians in real-world practice because apathy is often associated with poor prognosis (Starkstein et al, 2006) and poor response to treatment (Mega et al, 1999)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call